United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
The Pharma Data
OCTOBER 27, 2020
The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition. Sales and marketing. Cash, cash equivalents, and marketable investments. Cost of product sales. Dollar Change. .
40 
Let's personalize your content